TYGACIL® (tigecycline)

LENGTH OF AUTHORIZATION: Length of prescription (no more than 14 days); No refills.

REQUIRED LABS: MUST BE SUBMITTED WITH PA REQUEST AND DATED NO LATER THAN 14 DAYS PRIOR TO THERAPY (EG. CULTURE AND/OR SENSITIVITY).

REVIEW CRITERIA:

1. Patient must be ≥18 years of age.

2. Documentation must show previous trial and failure of a tetracycline product unless resistance is demonstrated. If no previous trial then clinically compelling documentation must be submitted justifying the use of this agent.

3. Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (MSSA), Staphylococcus aureus (MRSA), Streptococcus agalactiae, Streptococcus anginosus grp., Streptococcus pyogenes, and Bacteroides fragilis.

4. Complicated intraabdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (MSSA), Streptococcus anginosus grp., Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.

5. Community-acquired pneumonia due to penicillin-susceptible Streptococcus pneumoniae (including cases with concurrent bacteremia), beta-lactamase negative Haemophilus influenzae, and Legionella pneumophila.

DOSING AND ADMINISTRATION:

- The recommended dosage regimen is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions should be administered over approximately 30 to 60 minutes every 12 hours.
- The recommended duration of treatment for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days.
- The recommended duration of treatment for community-acquired bacterial pneumonia is 7 to 14 days.